Rituximab and CC-99282 for older frail patients with large b-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs, rituximab and CC-99282, as a first treatment for older adults with diffuse large b-cell lymphoma who are too frail for standard chemotherapy. The goal is to see if this gentler approach can effectively control the disease while being easier to tolerate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse large b-cell lymphoma (a type of blood cancer) and have not had any previous treatment for it.
- You are considered frail based on a special health assessment (age 80 or older and need help with daily activities or have multiple health problems).
- Your doctor has said you cannot receive a common type of chemotherapy called anthracycline-based therapy.
- You have at least one tumor that can be measured by a ct scan (1.5 cm or larger).
- Your blood counts, kidney function, and liver function are within acceptable ranges for the trial.
- You are able to swallow capsules or tablets and can follow the study visit schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial tests a combination of targeted drugs (Obutinib or Decitabine) with standard chemo (Rituximab, Cyclophosphamide, Prednisone) for elderly patients with newly diagnosed diffuse large B-cell lymphoma who cannot handle full-dose chemotherapy. The goal is to see if this approach is safer and works as well.
This trial tests a combination of two drugs — epcoritamab and a gentler chemo regimen (rituximab-mini CVP) — for older or frailer patients with newly diagnosed aggressive B-cell lymphoma who cannot tolerate standard intensive chemo. The goal is to find a safer but effective treatment option that still controls the lymphoma.
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
This study tests a combination of drugs (called R-mini-MCOP) in people 80 years or older with a type of lymphoma called DLBCL that has not been treated before. The goal is to see if this treatment can help control the lymphoma while being safe for older patients.
This trial tests a combination of three drugs (golcadomide, poseltinib, and rituximab) for people with a type of lymphoma that has returned or not responded to previous treatment. The goal is to see if this combination is safe and effective for those who cannot have a stem cell transplant.
Hear when a new Diffuse Large B Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.